NRD
PCRX icon

Nebula Research & Development’s Pacira BioSciences PCRX Stock Holding History

Nebula Research & Development’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13,561
Closed -$204K – 1061
2024
Q3 		$204K Buy
+13,561
New +$232K 0.02% 821

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Nebula Research & Development's PCRX Position: Q4 2024 in Review

Nebula Research & Development sold out of Pacira BioSciences (PCRX) in Q4 2024, closing a stake of 13,561 shares — an estimated $204K sold.

Nebula Research & Development first reported a position in PCRX in Q3 2024 and held it in 1 quarter. The position peaked at $204K in Q3 2024. 233 funds tracked by Wall St. Rank hold PCRX as of Q4 2024.

  • Nebula Research & Development reported no remaining Pacira BioSciences position as of Q4 2024 after selling out during the quarter.
  • Nebula Research & Development sold 13,561 Pacira BioSciences shares in Q4 2024, an estimated $204K.
  • Nebula Research & Development first reported a position in Pacira BioSciences in Q3 2024 and held it in 1 quarter.
  • Nebula Research & Development's Pacira BioSciences position peaked at $204K in Q3 2024.
  • 233 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2024.

Based on Nebula Research & Development's 13F filing for Q4 2024, filed 14 Feb 2025.